Table 3:
Significant predictors of cost
| P Value | Partial Eta2 | Exponentiated β-Coefficient (95% CI)b | ||
|---|---|---|---|---|
| Primary analysis: all ACLVOa (n = 341) | ||||
| FIV (mL) | <.0001 | 20.87% | 1.0037 (1.0029–1.0048) | |
| PH types 1 and 2 | <.0001 | 5.22% | 1.6399 (1.3050–2.0610) | |
| NIHSS | .0024 | 2.76% | 1.0161 (1.0057–1.0266) | |
| Obstructive sleep apnea | .0040 | 2.48% | 1.3391 (1.0981–1.6329) | |
| Age (yr) | .0089 | 2.06% | 0.9946 (0.9906–0.9986) | |
| Ipsilateral carotid stenosis | .0195 | 1.65% | 1.1902 (1.0285–1.3774) | |
| Subgroup analysis by treatment group | ||||
| Endovascular therapy (n = 133) | ||||
| FIV (mL) | .0003 | 10.03% | 1.0024 (1.0011–1.0037) | |
| PH type 1 | .0006 | 9.24% | 2.4942 (1.4926–4.1680) | |
| Obstructive sleep apnea | .0018 | 7.71% | 1.5211 (1.1727–1.9730) | |
| NIHSS | .0120 | 5.08% | 1.0206 (1.0046–1.0368) | |
| Ipsilateral carotid stenosis | .0290 | 3.85% | 1.2481 (1.0234–1.5221) | |
| mTICI scorec | .0364 | 1.79% | Multilevel variable | |
| IV tPA-only (n = 61) | ||||
| FIV (mL) | <.0001 | 29.11% | 1.0043 (1.0025–1.0060) | |
| NIHSS | .0300 | 7.99% | 1.0273 (1.0273–1.0524) | |
| No reperfusion therapy (n = 147) | ||||
| FIV (mL) | <.0001 | 27.92% | 1.0042 (1.0031–1.0053) | |
| PH types 1 and 2 | .0005 | 8.37% | 2.6371 (1.5458–4.4988) | |
| Obstructive sleep apnea | .0300 | 3.29% | 1.5057 (1.0407–2.1784) | |
| Age (yr) | .0330 | 3.20% | 0.9925 (0.9857–0.9937) | |
a
Controlled for treatment type: endovascular, IV-tPA, and no reperfusion therapy.
b
The exponentiated β-coefficient represents the multiplicative change in cost associated with an increase in 1 unit of a continuous variable (or the presence of a categoric variable), while holding all other variables constant.
c
Multilevel variable with F-distribution.